FDA panel rejects AstraZeneca trial design

Breast-cancer drug approvals usually follow a simple logic: a patient’s cancer worsens on scans, then treatment changes. AstraZeneca asked the FDA to bless something earlier and more experimental. The company wanted approval for camizestrant in patients whose blood test picked up an ESR1 mutation before imaging showed the disease had progressed. On April 30, the FDA’s Oncologic Drugs Advisory Committee voted 6-3 against that benefit-risk case, and the problem was less about toxicity than about proof. (astrazeneca.com) ### What drug was AstraZeneca trying to get through? Camizestrant is an oral SERD — a drug designed to degrade the estrogen receptor that helps drive many hormone receptor-positive breast cancers. AstraZeneca pitched it in combination with a CDK4/6 inhibitor for first-line treatment of HR-positive, HER2-negative advanced breast cancer after an ESR1 mutation emerges. That mutation is a known re(astrazeneca.com)ression. (astrazeneca.com) ### What was unusual about the strategy? The unusual part was not just the drug. It was the timing. Patients in SERENA-6 had not yet shown radiographic progression — scans had not clearly said the current regimen had failed. Instead, a circulating tumor DNA test flagged an ESR1 mutation, and AstraZeneca argued that molecular progression should be enough reason to swap in camizestrant while kee(astrazeneca.com)pproval. (biospace.com) ### What did the trial actually show? On its face, the headline number looked strong. In SERENA-6, median progression-free survival was 16.0 months with camizestrant versus 9.2 months with standard endocrine therapy after the ESR1 mutation was detected. That translated to a hazard ratio of 0.44 — roughly a 56% reduction in the risk of progression or death by that endpoint. Safety did not seem to b(biospace.com)nts showed up more often. (targetedonc.com) ### So why did the panel still say no? Because the panel did not think the trial cleanly answered the question that matters most: are patients actually better off from switching early, rather than just starting the clock earlier? Reviewers and several advisers zeroed in on the trial design, especially the nonstandard definition of progression-free survival and the lack of mature overall-survival data. The (targetedonc.com)wanted clearer evidence that patients gained meaningful time overall, not just time measured from a new starting line. (fiercebiotech.com) ### Why does “time zero” matter so much? Because in oncology, when you start counting can change what the benefit looks like. Imagine moving a chess clock to the moment one player notices trouble rather than the moment the position actually collapses. You may capture an earlier warning, but you also risk flattering the intervention if the comparison is no longer apples to apple(fiercebiotech.com) biological idea with an approval-standard evidence problem. (targetedonc.com) ### Was this a full rejection? Not exactly. Advisory committees do not make the final FDA decision, and AstraZeneca said it remains confident in the data. But the FDA usually takes these panels seriously, and the 6-3 vote is a clear warning that this application faces a tough path. AstraZeneca’s shares fell after the vote, which tells you investors heard the same message. (astrazeneca.com)atter beyond AstraZeneca? Because drugmakers have been trying to move cancer treatment earlier and make it smarter with blood tests, mutation tracking, and adaptive switching. This vote suggests the FDA is open to the idea in theory but still wants conventional proof that patients live longer or very clearly do better. In other words, biomarker-led precision medicine is not getting a free pass just because the biology makes sense. (fiercebiotech.com) ### Bottom line AstraZeneca brought the FDA a real oncology question — should doctors switch therapy when the blood says resistance has started, even before scans catch up? The panel’s answer was basically: maybe someday, but not on this evidence package. (fiercebiotech.com)